{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T13:24:36Z","timestamp":1786973076396,"version":"build-2736575974"},"reference-count":71,"publisher":"MDPI AG","issue":"16","license":[{"start":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T00:00:00Z","timestamp":1786924800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Clin. Med.","JCM"],"abstract":"<jats:p>Theranostics has transformed nuclear medicine from an imaging-focused discipline into a data-rich radiation medicine platform in which target expression, pharmacokinetics, tumor dose, and response can be measured in the same patient. This critical narrative review evaluates patient-specific integration of radiopharmaceutical therapy (RPT) with external-beam radiotherapy (EBRT), with emphasis on quantitative imaging, absorbed-dose estimation, spatial registration, biological interpretation, adaptation thresholds, and reporting. We performed a targeted search of PubMed\/MEDLINE, ClinicalTrials.gov, U.S. Food and Drug Administration records, professional-society guidance, and reference lists for English-language evidence available through 31 July 2026, prioritizing guidelines, regulatory documents, randomized and prospective trials, technical validation studies, and clinically informative retrospective series. Established RPT platforms are distinguished from investigational combined-modality applications and emerging or speculative technologies. Liver-directed Y-90 radioembolization combined with focal EBRT remains the most developed model, whereas head and neck, prostate, meningioma, lymphoma, and bone-dominant strategies illustrate distinct clinical geometries and levels of readiness. Across platforms, direct addition of absorbed dose in gray (Gy) is a geometric description, not automatically a biological endpoint; biologically effective dose (BED) and equivalent dose in 2-Gy fractions (EQD2) should be treated as model-based estimates with explicit assumptions. Future theranostic radiation medicine should therefore be built on prospective trials with prespecified dosimetry, uncertainty analysis, adaptation rules, and shared cross-modality reporting standards.<\/jats:p>","DOI":"10.3390\/jcm15166339","type":"journal-article","created":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T12:01:26Z","timestamp":1786968086000},"page":"6339","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Theranostics in Radiation Medicine: Integrating Radiopharmaceutical Therapy and External-Beam Radiotherapy"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6723-718X","authenticated-orcid":false,"given":"Senthamizhchelvan","family":"Srinivasan","sequence":"first","affiliation":[{"name":"Department of Radiation Medicine, School of Medicine, Indiana University, Indianapolis, IN 46202, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4461-1666","authenticated-orcid":false,"given":"Joseph A.","family":"Moore","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, School of Medicine, University of Minnesota, Minneapolis, MN 55455, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6202-6666","authenticated-orcid":false,"given":"Sarah","family":"Han-Oh","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, School of Medicine, Johns Hopkins University, Baltimore, MD 21287, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,8,17]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/s41573-020-0073-9","article-title":"Radiopharmaceutical therapy in cancer: Clinical advances and challenges","volume":"19","author":"Sgouros","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_2","first-page":"1007","article-title":"Theranostics in Perspective: White Paper","volume":"66","author":"Stokkel","year":"2025","journal-title":"J. Nucl. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"114538","DOI":"10.1016\/j.addr.2022.114538","article-title":"Imaging-guided targeted radionuclide tumor therapy: From concept to clinical translation","volume":"190","author":"Sun","year":"2022","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1515\/znc-2024-0043","article-title":"Navigating the landscape of theranostics in nuclear medicine: Current practice and future prospects","volume":"79","author":"Shah","year":"2024","journal-title":"Z. Naturforsch. C"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1007\/s00259-022-06028-9","article-title":"EANM practice guideline for quantitative SPECT-CT","volume":"50","author":"Dickson","year":"2023","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"38S","DOI":"10.2967\/jnmt.125.270852","article-title":"Radiation dosimetry in theranostics: A review","volume":"53","author":"Zanzonico","year":"2025","journal-title":"J. Nucl. Med. Technol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1007\/s00259-014-2824-5","article-title":"The evidence base for the use of internal dosimetry in clinical molecular radiotherapy","volume":"41","author":"Strigari","year":"2014","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_8","first-page":"89","article-title":"Combining dosimetry for targeted radionuclide and external beam therapies using the biologically effective dose","volume":"18","author":"Bodey","year":"2003","journal-title":"Cancer Biother. Radiopharm."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ijrobp.2003.12.031","article-title":"Application of the linear-quadratic model to combined modality radiotherapy","volume":"59","author":"Bodey","year":"2004","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1016\/j.ijrobp.2010.08.022","article-title":"A treatment planning method for sequentially combining radiopharmaceutical therapy and external radiation therapy","volume":"80","author":"Hobbs","year":"2011","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_11","first-page":"227","article-title":"Planning combined treatments of external beam radiation therapy and molecular radiotherapy","volume":"29","author":"Cremonesi","year":"2014","journal-title":"Cancer Biother. Radiopharm."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/j.clon.2021.09.004","article-title":"Combining external beam radiation and radionuclide therapies: Rationale, radiobiology, results, and roadblocks","volume":"33","author":"Abbott","year":"2021","journal-title":"Clin. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa1213755","article-title":"Alpha emitter radium-223 and survival in metastatic prostate cancer","volume":"369","author":"Parker","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.eururo.2020.11.013","article-title":"Activity and adverse events of actinium-225-PSMA-617 in advanced metastatic castration-resistant prostate cancer after failure of lutetium-177-PSMA","volume":"79","author":"Feuerecker","year":"2021","journal-title":"Eur. Urol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1200\/JCO.23.00573","article-title":"Prostate-specific membrane antigen-targeting alpha emitter via antibody delivery for metastatic castration-resistant prostate cancer: A phase I dose-escalation study of Ac-225-J591","volume":"42","author":"Tagawa","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S1470-2045(23)00638-1","article-title":"Actinium-225-PSMA radioligand therapy of metastatic castration-resistant prostate cancer (WARMTH Act): A multicentre, retrospective study","volume":"25","author":"Sathekge","year":"2024","journal-title":"Lancet Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"4740","DOI":"10.1158\/1078-0432.CCR-23-1983","article-title":"Fibroblast activation protein-targeted radioligand therapy with Lu-177-EB-FAPI for metastatic radioiodine-refractory thyroid cancer: First-in-human, dose-escalation study","volume":"29","author":"Fu","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1007\/s00259-025-07617-0","article-title":"Safety and efficacy of Lu-177-FAPI-XT radioligand therapy in advanced sarcoma and other cancer entities: First-in-human, dose-escalation study","volume":"53","author":"Liu","year":"2026","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.7150\/thno.92775","article-title":"Terbium radionuclides for theranostic applications in nuclear medicine: From atom to bedside","volume":"14","author":"Koole","year":"2024","journal-title":"Theranostics"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1016\/S1470-2045(25)00332-8","article-title":"First-in-human results of Tb-161-PSMA-I&T dual beta-Auger radioligand therapy in metastatic castration-resistant prostate cancer (VIOLET): A single-centre, phase 1\/2 study","volume":"26","author":"Buteau","year":"2025","journal-title":"Lancet Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa1607427","article-title":"Phase 3 trial of Lu-177-dotatate for midgut neuroendocrine tumors","volume":"376","author":"Strosberg","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1016\/S1470-2045(21)00572-6","article-title":"Lu-177-dotatate plus long-acting octreotide versus high-dose long-acting octreotide in midgut neuroendocrine tumours (NETTER-1): Final overall survival and long-term safety results","volume":"22","author":"Strosberg","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_23","unstructured":"U.S. Food and Drug Administration (2018). FDA Approves Lutetium Lu 177 Dotatate for Treatment of GEP-NETs."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","article-title":"Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer","volume":"385","author":"Sartor","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1016\/S0140-6736(24)01653-2","article-title":"Lu-177-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-na\u00efve patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): A phase 3 randomized trial","volume":"404","author":"Morris","year":"2024","journal-title":"Lancet"},{"key":"ref_26","unstructured":"U.S. Food and Drug Administration (2026, June 15). FDA Expands Pluvicto\u2019s Metastatic Castration-Resistant Prostate Cancer Indication, Available online: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-expands-pluvictos-metastatic-castration-resistant-prostate-cancer-indication."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1016\/S1470-2045(25)00189-5","article-title":"Health-related quality of life, pain, and symptomatic skeletal events with Lu-177-PSMA-617 in patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): An open-label, randomized, phase 3 trial","volume":"26","author":"Fizazi","year":"2025","journal-title":"Lancet Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1053\/j.semnuclmed.2024.01.011","article-title":"Theranostics of thyroid cancer","volume":"54","author":"Giovanella","year":"2024","journal-title":"Semin. Nucl. Med."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Gulec, S.A., Benites, C., and Cabanillas, M.E. (2024). Molecular perspectives in radioactive iodine theranostics: Current redifferentiation protocols for mis-differentiated thyroid cancer. J. Clin. Med., 13.","DOI":"10.3390\/jcm13133645"},{"key":"ref_30","unstructured":"U.S. Food and Drug Administration (2018). FDA Approves Iobenguane I 131 for Rare Adrenal Gland Tumors."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"623","DOI":"10.2967\/jnumed.118.217463","article-title":"Efficacy and safety of high-specific-activity I-131-MIBG therapy in patients with advanced pheochromocytoma or paraganglioma","volume":"60","author":"Pryma","year":"2019","journal-title":"J. Nucl. Med."},{"key":"ref_32","unstructured":"U.S. Food and Drug Administration (2026, August 02). FDA Approves Lutetium Lu 177 Vipivotide Tetraxetan with Androgen Receptor Pathway Inhibitor Therapy for Metastatic Androgen Pathway Modulation-Na\u00efve or -Sensitive Prostate Cancer, Available online: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-lutetium-lu-177-vipivotide-tetraxetan-androgen-receptor-pathway-inhibitor-therapy."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"van der Sar, E.C.A., Braat, A.J.A.T., van der Voort-van Zyp, J.R.N., van der Veen, B.S., van Leeuwen, P.J., de Vries-Huizing, D.M.V., Hendrikx, J.M.A., Lam, M.G.E.H., and Vogel, W.V. (2023). Tolerability of concurrent external beam radiotherapy and [177Lu]Lu-PSMA-617 for node-positive prostate cancer in treatment na\u00efve patients, phase I study (PROQURE-I trial). BMC Cancer, 23.","DOI":"10.1186\/s12885-023-10725-5"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.2967\/jnumed.123.265763","article-title":"Lesion dosimetry for Lu-177-PSMA-617 radiopharmaceutical therapy combined with stereotactic body radiotherapy in oligometastatic castration-sensitive prostate cancer","volume":"64","author":"Grkovski","year":"2023","journal-title":"J. Nucl. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.2967\/jnumed.125.270465","article-title":"Current developments in combining external-beam radiotherapy and Lu-177-labeled PSMA ligands for prostate cancer treatment","volume":"66","author":"Teunissen","year":"2025","journal-title":"J. Nucl. Med."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.nucmedbio.2020.01.003","article-title":"The effect of hypoxia on induction of strand breaks in plasmid DNA by alpha-, beta- and Auger electron-emitters Ra-223, Re-188, Tc-99m and DNA-binding Tc-99m-labeled pyrene","volume":"80\u201381","author":"Reissig","year":"2020","journal-title":"Nucl. Med. Biol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.nucmedbio.2021.05.005","article-title":"Applying radiobiology to clinical molecular radiotherapy","volume":"100\u2013101","author":"Murray","year":"2021","journal-title":"Nucl. Med. Biol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2680","DOI":"10.1007\/s00259-020-05147-5","article-title":"To go where no one has gone before: Necessity of radiobiology studies for exploration beyond the Holy Gray in radionuclide therapy","volume":"48","author":"Verburg","year":"2021","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"4118","DOI":"10.1007\/s00259-021-05560-4","article-title":"The limits of the Holy Gray in radioembolization and beyond","volume":"48","author":"Verburg","year":"2021","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s40658-018-0217-8","article-title":"Comparison of radiobiological parameters for Y-90 radionuclide therapy and external beam radiotherapy in vitro","volume":"5","author":"Gholami","year":"2018","journal-title":"EJNMMI Phys."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"135018","DOI":"10.1088\/1361-6560\/ab23c4","article-title":"Radiosensitivity of colorectal cancer to 90Y and the radiobiological implications for radioembolisation therapy","volume":"64","author":"Lee","year":"2019","journal-title":"Phys. Med. Biol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.nucmedbio.2021.04.003","article-title":"The salivary glands as a dose limiting organ of PSMA-targeted radionuclide therapy: A review","volume":"98\u201399","author":"Heynickx","year":"2021","journal-title":"Nucl. Med. Biol."},{"key":"ref_43","first-page":"189","article-title":"Myelotoxicity of peptide receptor radionuclide therapy of neuroendocrine tumors: A decade of experience","volume":"31","author":"Kesavan","year":"2016","journal-title":"Cancer Biother. Radiopharm."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"362","DOI":"10.2967\/jnumed.123.267167","article-title":"Rethinking dosimetry: The perils of extrapolated external-beam radiotherapy constraints to radionuclide therapy","volume":"65","author":"Strosberg","year":"2024","journal-title":"J. Nucl. Med."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.2967\/jnumed.124.269378","article-title":"Rethinking dosimetry: A European perspective","volume":"66","author":"Cicone","year":"2025","journal-title":"J. Nucl. Med."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"113815","DOI":"10.1016\/j.jconrel.2025.113815","article-title":"Nanoparticles in nuclear medicine: From diagnostics to therapeutics","volume":"383","author":"Wang","year":"2025","journal-title":"J. Control. Release"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1038\/s41570-024-00657-4","article-title":"Assembling a new generation of radiopharmaceuticals with supramolecular theranostics","volume":"8","author":"Drexler","year":"2024","journal-title":"Nat. Rev. Chem."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/s40658-024-00658-8","article-title":"A review of Lu-177 dosimetry workflows: How to reduce the imaging workloads?","volume":"11","author":"Vergnaud","year":"2024","journal-title":"EJNMMI Phys."},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Chen, X., Lu, J., Jiang, X., Afshar-Oromieh, A., Rominger, A., Shi, K., and Mok, G.S.P. (2023). Lu-177-PSMA dosimetry for kidneys and tumors based on SPECT images at two imaging time points. Front. Oncol., 10.","DOI":"10.3389\/fmed.2023.1246881"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"477","DOI":"10.2967\/jnumed.108.056036","article-title":"MIRD pamphlet No. 21: A generalized schema for radiopharmaceutical dosimetry\u2014Standardization of nomenclature","volume":"50","author":"Bolch","year":"2009","journal-title":"J. Nucl. Med."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"151","DOI":"10.2967\/jnumed.115.159012","article-title":"MIRD pamphlet No. 26: Joint EANM\/MIRD guidelines for quantitative Lu-177 SPECT applied for dosimetry of radiopharmaceutical therapy","volume":"57","author":"Ljungberg","year":"2016","journal-title":"J. Nucl. Med."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1007\/s00259-022-05727-7","article-title":"EANM dosimetry committee recommendations for dosimetry of Lu-177-labelled somatostatin-receptor- and PSMA-targeting ligands","volume":"49","author":"Chouin","year":"2022","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1007\/s00259-018-4136-7","article-title":"EANM practical guidance on uncertainty analysis for molecular radiotherapy absorbed dose calculations","volume":"45","author":"Gear","year":"2018","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"82S","DOI":"10.2967\/jnmt.125.270251","article-title":"The role of artificial intelligence in theranostics","volume":"53","author":"Currie","year":"2025","journal-title":"J. Nucl. Med. Technol."},{"key":"ref_55","first-page":"57","article-title":"Artificial intelligence in nuclear medicine physics and imaging","volume":"26","author":"Papachristou","year":"2023","journal-title":"Hell. J. Nucl. Med."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/jrr\/rrad090","article-title":"Revolutionizing radiation therapy: The role of artificial intelligence in clinical practice","volume":"65","author":"Kawamura","year":"2024","journal-title":"J. Radiat. Res."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"e43","DOI":"10.1002\/mp.12256","article-title":"Use of image registration and fusion algorithms and techniques in radiotherapy: Report of the AAPM Radiation Therapy Committee Task Group No. 132","volume":"44","author":"Brock","year":"2017","journal-title":"Med. Phys."},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Wang, T.H., Huang, P.I., Hu, Y.W., Lin, K.H., Liu, C.S., Lin, Y.Y., Liu, C.A., Tseng, H.S., Liu, Y.M., and Lee, R.C. (2018). Combined Yttrium-90 microsphere selective internal radiation therapy and external beam radiotherapy in hepatocellular carcinoma: From clinical aspects to dosimetry. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0190098"},{"key":"ref_59","first-page":"100612","article-title":"Stereotactic inverse dose planning after yttrium-90 selective internal radiation therapy in hepatocellular cancer","volume":"6","author":"Abbott","year":"2021","journal-title":"Adv. Radiat. Oncol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s40658-021-00391-6","article-title":"Y-90 selective internal radiation therapy: Evaluation of tumor control probability variation across dosimetric models","volume":"8","author":"Van","year":"2021","journal-title":"EJNMMI Phys."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1016\/j.ijrobp.2024.02.005","article-title":"Voxel-level dosimetry for combined iodine-131 radiopharmaceutical therapy and external beam radiotherapy treatment paradigms of head and neck cancer","volume":"119","author":"Adam","year":"2024","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"105496","DOI":"10.1016\/j.ebiom.2024.105496","article-title":"Safety and toxicity of iopofosine I-131 (CLR 131) with external beam radiation therapy in recurrent or metastatic head and neck cancer: Results of a phase 1 single-centre open-label study","volume":"111","author":"Bruce","year":"2025","journal-title":"eBioMedicine"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/1748-717X-7-99","article-title":"Combination of peptide receptor radionuclide therapy with fractionated external beam radiotherapy for treatment of advanced symptomatic meningioma","volume":"7","author":"Kreissl","year":"2012","journal-title":"Radiat. Oncol."},{"key":"ref_64","first-page":"29","article-title":"Long-term results of multimodal peptide receptor radionuclide therapy and fractionated external beam radiotherapy for treatment of advanced symptomatic meningioma","volume":"22","author":"Hartrampf","year":"2020","journal-title":"Clin. Transl. Radiat. Oncol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/j.ijrobp.2009.12.030","article-title":"External beam radiotherapy followed by Y-90 ibritumomab tiuxetan in relapsed or refractory bulky follicular lymphoma","volume":"79","author":"Burdick","year":"2011","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"328","DOI":"10.4149\/neo_2013_044","article-title":"A prospective randomized trial: A comparison of the analgesic effect and toxicity of Sm-153 radioisotope treatment in monotherapy and combined therapy including local external beam radiotherapy among metastatic castration-resistant prostate cancer patients with painful bone metastases","volume":"60","author":"Baczyk","year":"2013","journal-title":"Neoplasma"},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Hasan, H., Deek, M.P., Phillips, R., Hobbs, R.F., Malek, R., Radwan, N., Kiess, A.P., Dipasquale, S., Huang, J., and Caldwell, T. (2020). A phase II randomized trial of radium-223 dichloride and SABR versus SABR for oligometastatic prostate cancer (RAVENS). BMC Cancer, 20.","DOI":"10.1186\/s12885-020-07000-2"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1200\/JCO-25-00131","article-title":"Outcomes of radium-223 and stereotactic ablative radiotherapy versus stereotactic ablative radiotherapy for oligometastatic prostate cancers: The RAVENS phase II randomized trial","volume":"43","author":"Wang","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"e000635","DOI":"10.1136\/esmoopen-2019-000635","article-title":"Ra-223 for metastatic osteosarcoma: Combination therapy with other agents and external beam radiotherapy","volume":"5","author":"Anderson","year":"2020","journal-title":"ESMO Open"},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"International Commission on Radiation Units and Measurements (2010). Prescribing, Recording, and Reporting Photon-Beam Intensity-Modulated Radiation Therapy (IMRT). ICRU Report 83. J. ICRU, 10, 1\u2013106.","DOI":"10.1093\/jicru\/ndq002"},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"International Commission on Radiation Units and Measurements (2014). Prescribing, Recording, and Reporting of Stereotactic Treatments with Small Photon Beams. ICRU Report 91. J. ICRU, 14, 1\u2013160.","DOI":"10.1093\/jicru_ndw040"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/16\/6339\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T12:28:16Z","timestamp":1786969696000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/16\/6339"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,17]]},"references-count":71,"journal-issue":{"issue":"16","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["jcm15166339"],"URL":"https:\/\/doi.org\/10.3390\/jcm15166339","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,17]]}}}